Drug Description in Trials / DrugBank / KEGG DRUG
Search results
Showing 1 to 10 of 20 descriptions
No. | 薬物名(臨床試験情報から抽出) | DrugBank | KEGG DRUG | KEGG GENES | KEGG PATHWAY | 指定難病告示番号 | |||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 150 mg double-blinded secukinumab | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬1. 150 mg double-blinded secukinumab
| 1件: IL17A IL17A 💬1. 150 mg double-blinded secukinumab
| 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflam ... | 1件: 271 271 💬1. 150 mg double-blinded secukinumab
| |||||||||||||||||||||||||||||||||||
2 | 150 mg open-label secukinumab | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬2. 150 mg open-label secukinumab
| 1件: IL17A IL17A 💬2. 150 mg open-label secukinumab
| 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflam ... | 1件: 271 271 💬2. 150 mg open-label secukinumab
| |||||||||||||||||||||||||||||||||||
3 | 300 mg double-blinded secukinumab | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬3. 300 mg double-blinded secukinumab
| 1件: IL17A IL17A 💬3. 300 mg double-blinded secukinumab
| 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflam ... | 1件: 271 271 💬3. 300 mg double-blinded secukinumab
| |||||||||||||||||||||||||||||||||||
4 | SECUKINUMAB | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬4. SECUKINUMAB
| 1件: IL17A IL17A 💬4. SECUKINUMAB
| 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflam ... | 8件: 13 13, 37, 41, 46, 107, 160, 269, 271 💬4. SECUKINUMAB
| |||||||||||||||||||||||||||||||||||
5 | Secukinumab (150 mg) | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬5. Secukinumab (150 mg)
| 1件: IL17A IL17A 💬5. Secukinumab (150 mg)
| 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflam ... | 1件: 271 271 💬5. Secukinumab (150 mg)
| |||||||||||||||||||||||||||||||||||
6 | Secukinumab (75 mg) | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬6. Secukinumab (75 mg)
| 1件: IL17A IL17A 💬6. Secukinumab (75 mg)
| 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflam ... | 1件: 271 271 💬6. Secukinumab (75 mg)
| |||||||||||||||||||||||||||||||||||
7 | Secukinumab (AIN457) | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬7. Secukinumab (AIN457)
| 1件: IL17A IL17A 💬7. Secukinumab (AIN457)
| 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflam ... | 1件: 46 46 💬7. Secukinumab (AIN457)
| |||||||||||||||||||||||||||||||||||
8 | Secukinumab (AIN457) 150 mg s.c. | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬8. Secukinumab (AIN457) 150 mg s.c.
| 1件: IL17A IL17A 💬8. Secukinumab (AIN457) 150 mg s.c.
| 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflam ... | 1件: 271 271 💬8. Secukinumab (AIN457) 150 mg s.c.
| |||||||||||||||||||||||||||||||||||
9 | Secukinumab 150 mg | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬9. Secukinumab 150 mg
| 1件: IL17A IL17A 💬9. Secukinumab 150 mg
| 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflam ... | 1件: 41 41 💬9. Secukinumab 150 mg
| |||||||||||||||||||||||||||||||||||
10 | Secukinumab 150 mg (2 injections per dose | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬10. Secukinumab 150 mg (2 injections per dose
| 1件: IL17A IL17A 💬10. Secukinumab 150 mg (2 injections per dose
| 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflam ... | 1件: 269 269 💬10. Secukinumab 150 mg (2 injections per dose
|